UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/592,922	12/11/2006	Gregory Royce Collier	DAVI221.003APC	5780
20995 7590 05/22/2009 KNOBBE MARTENS OLSON & BEAR LLP			EXAMINER	
2040 MAIN ST	REET	GAMETT, DANIEL C		
FOURTEENTH FLOOR IRVINE, CA 92614			ART UNIT	PAPER NUMBER
			1647	
			NOTIFICATION DATE	DELIVERY MODE
			05/22/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

jcartee@kmob.com eOAPilot@kmob.com

	Application No.	Applicant(s)
	10/592,922	COLLIER ET AL.
Office Action Summary	Examiner	Art Unit
	DANIEL C. GAMETT	1647
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the o	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period verailure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on <u>06 At</u> This action is FINAL . 2b)☑ This Since this application is in condition for alloware closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 1-23 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-23 are subject to restriction and/or expressions.	vn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D: 5) Notice of Informal F 6) Other:	ate

Application/Control Number: 10/592,922 Page 2

Art Unit: 1647

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-8 and 15-23, drawn to an isolated compound which is a ligand of or otherwise interacts with a protein which comprises an amino acid sequence as set forth in SEQ ID NO: 2.

Group II, claim(s) 9, in part, drawn to an agonist of the isolated compound of claim 1.

Group III, claim(s) 9, in part, drawn to an antagonist of the isolated compound of claim 1.

Group IV, claim(s) 10 and 11, drawn to a method of identifying a ligand of the protein FIT.

Group V, claim(s) 12, drawn to method for modulating expression of genetic material encoding a FIT ligand.

Group VI, claim(s) 13 and 14, drawn to methods of modulating activity of FIT in a mammal.

2. The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The PCT rule defines special technical features as technical features that identify a contribution each of the claimed inventions, considered as a whole, makes over prior art. Claim 1 is anticipated by prior art. Claim 1 is drawn to isolated compound which is a ligand of or otherwise interacts with a protein which comprises an amino acid sequence as set forth in SEQ ID NO: 2. Dependent claim 8 identifies endophilins 1 and 3 as species of the generic product of Group I. Isolated endophilins were known in the prior art as disclosed by Tang et al., PNAS Vol. 96(22): 12559-12564 (of record). Therefore, claim 1 lacks a special technical feature and cannot share one with the other claims.

Art Unit: 1647

Group II recites the special technical feature, agonist of the isolated compound of claim 1, which is not required by the methods or the products of Groups I and III-VI.

Group III recites the special technical feature, antagonist of the isolated compound of claim 1, which is not required by the methods or the products of Groups I, II, and IV-VI.

Group IV recites the special technical feature, method of identifying a ligand of the protein FIT, which is not required by the methods or the products of Groups I-III, V, and VI.

Group V recites the special technical feature, method of modulating expression of genetic material encoding a FIT ligand, which is not required by the methods or the products of Groups I-IV and VI.

Group VI recites the special technical feature, method of modulating activity of FIT in a mammal, which is not required by the methods or the products of Groups I-V.

3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel C. Gamett, PhD., whose telephone number is (571)272-1853. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath N. Rao can be reached on 571 272 0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/592,922

Art Unit: 1647

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Page 4

/Daniel C Gamett/ Examiner, Art Unit 1647